Profile data is unavailable for this security.

About the company

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

  • Revenue in USD (TTM)49.53bn
  • Net income in USD7.21bn
  • Incorporated1996
  • Employees110.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:VTX since
Amblyotech IncDeal completed20 Apr 202020 Apr 2020Deal completed-11.70%--
The Medicines CoDeal completed24 Nov 201924 Nov 2019Deal completed-15.42%7.38bn
Data delayed at least 15 minutes, as of Aug 11 2020 13:25 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Takeda Pharmaceutical Co Ltd30.61bn1.13bn56.84bn47.50k49.771.279.011.8676.5076.502,073.572,998.370.2481.254.2068,300,180.000.91561.631.082.0768.0668.863.695.280.84441.360.5197164.4456.9313.11-67.28--14.900.00
Bayer AG51.04bn-8.56bn65.25bn101.17k--1.56--1.28-7.42-5.7144.2936.340.34511.703.18418,776.00-5.773.25-7.664.1060.2360.77-16.717.560.61915.160.535382.9118.521.0575.47-
Chugai Pharmaceutical Co Ltd6.93bn1.80bn76.71bn7.39k41.638.75--11.07115.87115.87446.25551.130.71311.593.6499,272,250.0018.5210.3421.6912.2563.2354.4525.9715.803.69--0.0049.7618.358.2770.3625.3226.1323.87
Novartis AG (ADR)49.53bn7.21bn204.14bn110.00k26.273.5016.,624.906.016.227.997.6971.0468.3014.5617.320.5778482.830.392381.915.67-1.94-44.19-7.69-7.890.533
Roche Holding AG65.82bn14.15bn296.42bn97.74k20.968.5115.014.5014.9714.9769.6536.870.75092.495.15616,749.4017.0313.6125.2220.3272.3670.9922.6819.480.931126.720.301771.338.135.3128.977.667.992.38
Data as of Aug 11 2020. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD

Institutional shareholders

4.46%Per cent of shares held by top holders
HolderShares% Held
PRIMECAP Management Co.as of 31 Mar 202024.03m0.97%
Dodge & Coxas of 31 Mar 202022.94m0.93%
Loomis, Sayles & Co. LPas of 31 Mar 202010.41m0.42%
Fisher Asset Management LLCas of 30 Jun 20208.83m0.36%
Franklin Mutual Advisers LLCas of 31 Mar 20208.80m0.36%
Renaissance Technologies LLCas of 31 Mar 20208.49m0.34%
Mawer Investment Management Ltd.as of 31 Mar 20207.72m0.31%
UBS Financial Services, Inc.as of 30 Jun 20206.72m0.27%
Managed Account Advisors LLCas of 31 Mar 20206.26m0.25%
Aristotle Capital Management LLCas of 31 Mar 20205.88m0.24%
More ▼
Data from 31 Mar 2020 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.